Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Champions Oncology, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 38 | 35 | −3 |
| Shares | 6.66M | 6.28M | −377.2K (−5.7%) |
| Value | $68.5M | $64.1M | −$4.34M (−6.3%) |
New holders (2)
Institutions that held Champions Oncology, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Federated Hermes, Inc. | 5,894 | $59.0K | 0.00% |
| Total Clarity Wealth Management, Inc. | 713 | $7.00K | 0.00% |
Sold out (5)
Institutions that held Champions Oncology, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Roubaix Capital, LLC | 351,507 | $3.61M |
| Bank of America Corp | 1,430 | $15.0K |
| Panagora Asset Management Inc | 278 | $3.00K |
| New York State Common Retirement Fund | 62 | $1.00K |
| UBS Group AG | 76 | $1.00K |